Trade Marks AstraZeneca, the AstraZeneca logotype, and the AstraZeneca symbol are all trade marks of the Group.
The following brand names which appear in italics in this Annual Report are trade marks of the Group: Trade mark 2 2 Arimidex Diprivan Marcaine Seloken 1 Atacand Duzallo Movantik Seroquel 2 Atacand HCT EMLA Moventig Seroquel XR 1 2 Atacand Plus Farxiga Naropin Symbicort BCise Fasenra Nexium Symbicort SMART Bevespi Aerosphere Faslodex Onglyza Symbicort Turbuhaler Brilinta Fluenz Plendil Symlin 5 Brilique FluMist Pressair Synagis Bydureon Forxiga Prilosec Tagrisso Byetta Genuair Provisacor Toprol-XL 3 Calquence Imdur Pulmicort Turbuhaler 2 6 Carbocaine Imfinzi Pulmicort Flexhaler Vimovo Casodex Iressa Pulmicort Respules Xigduo 2 2 Citanest Kombiglyze Pulmicort Turbuhaler Xylocaine 7 Cosudex Komboglyze Qtern Zavicefta Crestor Losec Respules Zoladex 4 8 Daliresp Lokelma Rhinocort Zomig 4 Daxas Lynparza Rhinocort Aqua Zurampic 1 AstraZeneca divested these trade marks in Europe to Cheplapharm effective 28 September 2018.
2 AstraZeneca divested these trade marks to Aspen group effective 1 November 2017.
3 AstraZeneca assigned this trade mark to Everest Future Limited effective 1 May 2016.
4 AstraZeneca assigned Rhinocort and Rhinocort Aqua to Cilag outside the US effective 5 December 2016.
5 AstraZeneca owns this trade mark in the US only.
AbbVie owns it in the rest of the world.
6 AstraZeneca divested the global rights excluding the US and Japan for this trade mark to Grnenthal, effective 3 December 2018.
7 AstraZeneca assigned this trade mark to Pfizer Inc. effective 23 December 2016.
8 AstraZeneca assigned the rights to this trade mark outside Japan to Grnenthal effective 7 June 2017.
In Japan, AstraZeneca divested this product to Sawai Pharmaceutical effective 3October2017.
The following brand names which appear in italics in this Annual Report are trade marks licensed to the Group by the entities set out below: Trade mark Licensor or Owner Anticalin Pieris AG Duaklir Almirall, S. A. Eklira Almirall, S. A. Epanova Chrysalis Pharma AG Fluimucil Zambon S. p. A. Linzess Ironwood Lumoxiti Innate Pharma Tudorza Almirall, S. A.
The following brand names which appear in italics throughout this Annual Report are not owned by or licensed to the Group and are owned by the entities set out below: Trade mark Owner Imbruvica Depending on geography, the trade mark is owned by Pharmacyclics, Inc. Johnson & Johnson or Janssen Pharmaceutica NV.
Keytruda MSD messenger RNA Therapeutics Moderna 238 AstraZeneca Annual Report & Form 20-F Information 2018 Additional Information
